Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 5Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Noonan Syndrome 5 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Antineoplastic Agents × 1 year × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡